In the News

View the latest developments and press releases from Absolute Antibody.

Absolute Antibody Increases Automation Capabilities and Expands Production Facility

Spotlight On: Z-DNA Antibodies

Engineering ACE2 Fc Fusion Proteins For COVID-19 Prophylaxis

Monkeypox Virus Antibodies for Research and Diagnostics

Absolute Antibody Expands Prometheus™ Antibody Humanization Service to Include Non-Murine Origin Species

PD-1 Fc Silent™ Antibody Improves Anti-Tumor Activity in Mice

Absolute Antibody Licenses Novel Fc Silencing Technology from mAbsolve

Absolute Antibody Wins Made in the North East Award

Dog Antibodies for Research on Comparative Oncology and Infectious Disease

Anti-SARS-CoV-2 Antibodies Bind to the Coronavirus Omicron Variant

Confirmed Pathogen-Free Expression for All Absolute Antibody Products

Recombinant Engineered Antibodies Against Anthrax

Overcoming Obstacles to Antibody Production with Hybridoma Sequencing

Attending the Queen’s Awards Reception at Windsor Castle

See our Services in Action: Recent publications highlighting our recombinant antibody technology

CHXpress™ Transient CHO Expression Service

Multi-Tag Protein 2 (MTP2), An Engineered Fusion Protein with Epitope Tags

Anti-SARS-CoV-2 Antibodies Bind to the Coronavirus Delta Variant

Anti-TIGIT Antibodies and their Fc Dependency

A Year in the Life of Absolute Antibody Employee, Ella

Multi-Tag Control Protein, A Genetically Engineered Synthetic Fusion Protein

Getting Started with Bispecifics: Go-to formats to fit your research project

OspA Antibodies for Lyme disease (Borreliosis) Research and Diagnostics

Anti-SARS-CoV-2 Antibodies Bind to Coronavirus Variants

Tumor Marker Antigens for the Detection and Treatment of Cancer

Guide to Recombinant Antibody Engineering

Transient Antibody Expression Platform Drives Batch-to-Batch Reproducibility for COVID-19 Diagnostic Assay

Large-Scale Production of the First Pig Influenza Antibodies

Developing a Panel of Recombinant Antibody Controls for Cytokine Release Assays

Anti-SARS-CoV-2 Antibody CR3022 Binds to Coronavirus Variants